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OBJECTIVES This study was designed to determine the time course of nitrate interaction with tadalafil, a
phosphodiesterase 5 (PDE5) inhibitor with a half-life (t1/2) of 17.5 h.
BACKGROUND The PDE5 inhibitors augment the blood pressure (BP)-lowering effects of nitrates, yet the
time course of this interaction is unclear. Recent guidelines from the American College of
Cardiology/American Heart Association recommend that nitrates be withheld for 24 h after
taking sildenafil (t1/2  4 h).
METHODS Male subjects (n 150) received seven consecutive daily doses of placebo or tadalafil (20 mg).
On day 7 and beyond, subjects received repeated doses of sublingual nitroglycerin (0.4 mg)
after the last dose of placebo or tadalafil. After a 10- to 21-day washout period, subjects
crossed over to either placebo or tadalafil, and nitrate dosing was repeated.
RESULTS In response to nitroglycerin at 4, 8, and 24 h, standing systolic BP fell below 85 mm Hg in
more subjects on tadalafil compared with placebo (p  0.05), with no difference in the
response to nitroglycerin at 48, 72, and 96 h (p  0.2). Similar observations were made for
standing diastolic BP 45 mm Hg, decrease in systolic BP 30 mm Hg, and decrease in
diastolic BP 20 mm Hg. Nitroglycerin also evoked greater mean maximal decreases in
standing systolic BP at 8 and 24 h after taking tadalafil versus placebo (p  0.02), with no
significant difference at 48, 72, or 96 h (p  0.49).
CONCLUSIONS The hemodynamic interaction between tadalafil and sublingual nitroglycerin lasted 24 h, but
was not seen at 48 h and beyond. Similar to other PDE5 inhibitors, tadalafil should not be
administered in combination with organic nitrates. (J Am Coll Cardiol 2003;42:1855–60)
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Phosphodiesterase 5 (PDE5) inhibitors such as sildenafil
and tadalafil interact with organic nitrates to result in a
synergistic drop in blood pressure (BP) (1–3). Organic
nitrates donate nitric oxide, which stimulates guanylate
cyclase to catalyze the formation of cyclic guanosine mono-
phosphate (cGMP). Cyclic guanosine monophosphate de-
creases calcium flux into smooth muscle cells evoking
relaxation of arteries, arterioles, and sinusoids of the corpus
cavernosum and resulting in improved erectile function (4).
The actions of cGMP are terminated by PDE5 (3,5,6).
Administration of a nitric oxide donor with a PDE5
inhibitor can evoke a large build-up of cGMP, marked
vasodilation, and in some patients frank hypotension (1).
Thus, organic nitrate use remains an absolute contraindica-
tion to the use of PDE5 inhibitors. One concern is: when is
it safe to administer nitrates to a patient who has taken a
PDE5 inhibitor and then develops angina? Established
guidelines recommend that nitrates not be given until 24 h
(6 half-lives) after taking sildenafil (7).
Tadalafil is an effective treatment for erectile dysfunction
and has a half-life (t1/2) of 17.5 h (8). Previous studies
showed there was little interaction with sublingual nitrate
26 h after an oral dose of 5 or 10 mg tadalafil when subjects
remained supine or sitting (3). However, there are no data
with 20 mg of tadalafil (a dose to be used clinically) nor are
there data that follow changes in BP when nitrate is
administered beyond 26 h after dosing. Our objective was to
determine whether 20 mg of tadalafil augments the hypo-
tensive response to sublingual nitroglycerin dosed 2 to 96 h
after tadalafil administration.
METHODS
This was a randomized, placebo-controlled, double-blind,
two-period, cross-over, multi-center study. The study was
approved by institutional review committees, and each
subject gave written, informed consent. A total of 166 men
entered the study (mean age 57  11 years, range 40 to 83
years). The subjects were evaluated as a group and were also
split into four subpopulations that included men with
diabetes (mean age 60  9.5 years, range 41 to 81 years,
n  32), and three populations of otherwise healthy men
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(men 40 to 55 years [mean age  46 4.5 years, n 
63], men 55 to 60 years [mean age  58  1.7 years,
n  25], and men 60 years [mean age  69  5.7 years,
n  46]).
Subjects were Caucasian (n 151), Afro-Caribbean (n
11), and Asian (n  4). Ten subjects were hypertensive, 43
smoked tobacco, and 133 reported at least occasional
alcohol intake. A total of 150 out of 166 men completed the
study, including 26 subjects 70 years.
During treatment period 1, subjects received seven con-
secutive daily doses of either tadalafil (20 mg) or placebo.
The dosing of tadalafil 20 mg to steady state results in
plasma concentrations that are 1.6-fold higher than those
observed with a single 20 mg dose. On day 7, after a final
dose of either tadalafil or placebo, sublingual nitroglycerin
(0.4 mg) was administered at 2 (supine only), 4, 8, 24, 48,
72, and 96 h post-tadalafil or placebo. After a washout
period of 10 to 21 days, subjects were crossed over in
treatment period 2 to either placebo or tadalafil.
A DINAMAP PRO (GE Medical Systems) noninvasive
BP system was used to measure BP and heart rate. Supine
BP was measured after 30 s in the supine position and
standing BP was measured 2 min after standing. Heart rate
and BP were measured on days 1 to 6 pre-dose, on day 7
pre-dose, 1 h post-tadalafil or placebo dosing, and before
and for 2 h after each nitroglycerin dose. The first nitro-
glycerin dose was administered 2 h after the final dose of
placebo or tadalafil to coincide with the maximum plasma
concentration of tadalafil. Because previous studies showed
that the hypotensive effect of nitroglycerin is augmented 2 h
after tadalafil, only supine measurements were made follow-
ing the 2-h nitroglycerin administration in the interest of
safety.
End points. PRIMARY END POINT. The primary end point
was to test the null hypothesis that, after taking sublingual
nitroglycerin, the percentage of subjects having a minimum
standing systolic BP 85 mm Hg after tadalafil (20 mg)
does not differ from placebo. This hypothesis was tested
separately following nitroglycerin at 4, 8, 24, 48, 72, and
96 h after either tadalafil or placebo.
SECONDARY END POINTS. The secondary end points were
to test the hypotheses that tadalafil compared to placebo
does not augment the hypotensive response to sublingual
nitroglycerin based on frequency of subjects having: 1 and 2)
a minimum standing and supine diastolic BP 45 mm Hg;
3 and 4) a decrease in standing and supine systolic BP 30
mm Hg; 5 and 6) a decrease in standing and supine diastolic
BP 20 mm Hg; and 7) a minimum supine systolic BP
85 mm Hg. We also analyzed the mean maximal decrease
in standing and supine systolic and diastolic BP and
examined the tolerability of nitroglycerin given at the
various times following tadalafil.
Statistics. Frequencies of subjects experiencing potentially
clinically significant BP findings were analyzed by repeated-
measures logistic regression (9), except for time-points at
which no subjects on one of the two treatments experienced
a particular clinically significant finding in which case a
non-parametric method (Prescott test) was used (10). Odds
ratios, p values, and 95% confidence limits were calculated
for the comparisons between tadalafil and placebo. Mean
maximal decreases in BP were analyzed using a linear mixed
effects model (9). Differences in least-squares means,
p values, and 95% confidence limits were calculated for the
comparisons between tadalafil and placebo. All hypothesis
tests were two-sided. No adjustment was made to p values
for multiple comparisons.
RESULTS
Figure 1 shows that the decreases in mean systolic and
diastolic BP in response to nitroglycerin were greater after
tadalafil compared with placebo at 4, 8, and 24 h, but were
similar at 48, 72, and 96 h.
Table 1 shows that the percentage of subjects experienc-
ing episodes of standing systolic BP 85 mm Hg after
nitroglycerin (the primary end point) was significantly
greater in the presence of tadalafil compared with placebo
from 4 to 24 h post-tadalafil or placebo, with no significant
difference at 48, 72, or 96 h. Analysis of the other outlier
criteria in Table 1 shows the same general pattern, with no
significant treatment differences in the response to nitro-
glycerin at 48 to 96 h post-tadalafil or placebo.
Table 2 shows that the number of episodes of clinically
significant BP effects was also greater for all parameters
following nitroglycerin from 2 to 24 h post-tadalafil com-
pared with placebo. After 24 h, the number of clinically
significant hypotensive episodes was similar following ni-
troglycerin in the presence of tadalafil versus placebo, and in
15 of 24 comparisons it was higher after placebo.
We also analyzed maximal decreases in BP. The mean
maximal decreases in standing systolic and diastolic BP
were greater in the tadalafil versus placebo treatment period
after the 8- and 24-h doses of nitroglycerin (p 0.02), with
no significant differences at 48, 72, and 96 h (p  0.33)
(data not shown). Similar responses were observed for
nitroglycerin-induced mean maximal decreases in supine
systolic and diastolic BP, with no differences at 48 to 96 h
after tadalafil compared with placebo (p  0.06).
The compensatory heart rate responses to nitroglycerin-
induced decreases in BP were similar after tadalafil com-
pared with placebo (Fig. 2). In both the standing and supine
positions, the differences in mean maximal increases
(tadalafil minus placebo) in heart rate ranged from 1.6 to
Abbreviations and Acronyms
BP  blood pressure
cGMP  cyclic guanosine monophosphate
PDE5  phosphodiesterase 5
t1/2  half-life
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2.3 beats/min. Although some of the mean differences were
statistically significant, they were not of sufficient magnitude
to be considered clinically significant.
In the analysis of subpopulations, tadalafil did not interact
with nitroglycerin to further lower BP at 48 h or beyond in
subjects with diabetes or in subjects 60 years of age.
The data in Table 3 show that headache, myalgia, back
pain, dizziness, dyspepsia, flushing, and postural dizziness
were the most frequently observed adverse events. Most
adverse events were mild in severity. It is noteworthy that
the frequency of dizziness was similar after tadalafil or
placebo, with most episodes of dizziness occurring during
the period of nitroglycerin administration. One subject on
placebo treatment experienced a serious adverse event of
sinus arrest following nitroglycerin given 24 h after the final
dose of placebo. The sinus arrest resolved spontaneously and
this subject was withdrawn from the study. No serious
adverse events occurred in subjects taking tadalafil.
DISCUSSION
The main finding of this study was that tadalafil augmented
the hypotensive effect of sublingual nitroglycerin given from
2 to 24 h after the last dose of tadalafil. This interaction was
no longer detectable when nitroglycerin was administered
48 to 96 h after tadalafil. Also, no clinically significant
differences existed in the compensatory heart rate responses
irrespective of the time nitroglycerin was given after tadalafil
or placebo.
Figure 1. Mean standing systolic and diastolic blood pressure (BP) in tadalafil (20 mg)- and placebo-treated subjects. Sublingual nitroglycerin (0.4 mg) is
indicated by the dashed vertical line. The 4- to 96-h time intervals represent time of nitroglycerin administration after the last dose of tadalafil or placebo.
In each graph, the upper set of curves represent systolic BP and the lower set of curves represent diastolic BP. Standard deviation for systolic and diastolic
BP ranged from 12 to 19 mm Hg and 9 to 13 mm Hg, respectively.
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Tadalafil 20 mg was generally well tolerated. Compared
with placebo, the incidence of myalgia and back pain during
tadalafil treatment was markedly higher. Myalgia and back
pain have been reported for the PDE5 inhibitors, especially
with daily dosing (7). Most of the episodes were mild in
severity, with a peak incidence occurring at two to three days
of the seven consecutive daily dosing period. The incidence
decreased with continued daily dosing of 20 mg tadalafil,
and only 2 of 166 subjects discontinued the study as a result
of myalgia or back pain. The myalgia that is sometimes
observed with PDE5 inhibitors has not been associated with
any significant underlying etiology such as elevations in
creatine kinase (7).
Previous studies have reported an interaction between
PDE5 inhibitors and organic nitrates (1–3). These studies
have shown that both tadalafil and sildenafil increased the
frequency of subjects having clinically significant decreases
in BP in response to sublingual nitroglycerin compared with
placebo (1–3). Webb et al. (2) also demonstrated that
subjects were less tolerant of an intravenous infusion of
nitroglycerin given 1 h after sildenafil 25 mg compared with
placebo, and when subjects were given sublingual nitroglyc-
erin 1 h after taking sildenafil 25 mg, they experienced a
four-fold greater decrease in systolic BP compared with
placebo (2). Although these studies described the interac-
tion between nitrates and PDE5 inhibitors (1–3), none of
them were designed to robustly evaluate the time course of
the interaction. Our data extend these studies by measuring
the time course of the nitrate-tadalafil interaction out to
96 h. Further studies to better evaluate the extent of the
interaction at time points between 24 and 48 h post-tadalafil
dosing would be of interest from both a basic science and
clinical perspective.
Tadalafil administration with nitrates is contraindicated.
Table 1. Percentage of Subjects Experiencing Clinically Important Blood Pressure Findings (Tadalafil/Placebo)
Criteria
Nitroglycerin Dose (h)
2 4 8 24 48 72 96
Standing
Systolic 85 mm Hg NP 46/31
[0.001]
31/21
[0.008]
41/32
[0.028]
28/27
[0.754]
23/28
[0.210]
27/25
[0.687]
Diastolic 45 mm Hg NP 19/6
[0.001]
12/5
[0.018]
16/8
[0.010]
11/13
[0.581]
8/10
[0.582]
6/7
[0.807]
Decrease in systolic 30 mm Hg NP 25/22
[0.423]
30/17
[0.002]
48/33
[0.002]
35/29
[0.133]
36/32
[0.338]
33/30
[0.416]
Decrease in diastolic 20 mm Hg NP 15/10
[0.126]
18/13
[0.158]
31/20
[0.010]
26/22
[0.263]
22/22
[0.891]
18/17
[0.766]
Supine
Systolic 85 mm Hg 12/5
[0.020]
12/4
[0.005]
7/2
[0.016]
8/3
[0.012]
3/3
[0.700]
3/2
[0.560]
3/2
[0.651]
Diastolic 45 mm Hg 4/1
[0.117]
5/4
[0.503]
4/1
[0.054]
2/2
[0.837]
2/1
[0.177]
1/2
[0.184]
1/1
[0.996]
Decrease in systolic 30 mm Hg 8/4
[0.074]
3/2
[0.646]
4/2
[0.320]
10/3
[0.016]
6/8
[0.628]
3/7
[0.066]
8/4
[0.126]
Decrease in diastolic 20 mm Hg 8/3
[0.017]
3/1
[0.136]
5/1
[0.047]
6/1
[0.049]
3/2
[0.700]
3/6
[0.190]
1/3
[0.215]
Data are presented as tadalafil/placebo and [p value for odds ratio]; n  154 to 157. The p value for the test of the null hypothesis of an odds ratio of 1 (corresponding to no
treatment effect relative to placebo) was calculated separately for each time point (2, 4, 8, 24, 48, 72, and 96 h) for each of the criteria using a repeated measures logistic regression
model accounting for the crossover design, with terms for treatment and period.
NP  not performed.
Table 2. Number of Clinically Important Blood Pressure Findings (Tadalafil/Placebo)
Criteria
Nitroglycerin Dose (h)
2 4 8 24 48 72 96
Standing
Systolic 85 mm Hg NP 229/149 119/89 157/115 104/116 74/101 75/91
Diastolic 45 mm Hg NP 67/29 48/21 65/37 34/38 29/34 11/25
Decrease in systolic 30 mm Hg NP 106/67 118/56 181/111 146/142 129/147 128/152
Decrease in diastolic 20 mm Hg NP 55/32 67/36 103/54 80/56 64/70 48/53
Supine
Systolic 85 mm Hg 46/22 55/29 41/10 25/10 10/10 14/7 10/8
Diastolic 45 mm Hg 10/3 15/10 25/6 14/9 10/6 5/8 3/8
Decrease in systolic 30 mm Hg 51/7 6/4 28/10 30/5 20/36 9/22 23/16
Decrease in diastolic 20 mm Hg 39/11 7/1 28/3 23/4 4/3 23/21 1/8
Data are presented as tadalafil/placebo. n  154 to 157.
NP  not performed.
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As is the case with sildenafil (11), physicians and paramedics
need to be aware of this potentially serious interaction.
Thus, if a patient presents with chest pain, it will be
imperative to question whether the patient has used a PDE5
inhibitor. If the patient has taken tadalafil within 48 h, then
organic nitrates should not be given. Furthermore, if ni-
trates are deemed medically necessary 48 h or more after the
use of tadalafil, they should be administered under close
medical supervision with hemodynamic monitoring. It is
noteworthy that in up to 33% of patients on placebo,
nitroglycerin decreased standing BP 30 mm Hg. Thus,
one should always be aware of the potentially marked
hypotensive effects of nitrates.
If a patient takes tadalafil and reports chest pain within
48 h, it would be prudent to use non-nitrate anti-anginal
agents (7). Beta-blockers, calcium channel blockers, mor-
phine, oxygen, and aspirin could all be considered for
treating ischemic chest pain, but nitrates should be avoided.
Should a patient present within 48 h after taking tadalafil
with an acute myocardial infarction, there is no contraindi-
cation to using usual therapy such as aspirin, heparin,
percutaneous coronary intervention, or thrombolytics; but
again, nitrates should not be given.
In conclusion, the hypotensive effect of sublingual nitro-
glycerin was augmented by tadalafil compared with placebo
for 24 h following tadalafil administration, with no differ-
ence in the hypotensive responses at 48 to 96 h following
Figure 2. Mean standing heart rate in tadalafil (20 mg)- and placebo-treated subjects. Sublingual nitroglycerin (0.4 mg) is indicated by dashed vertical line.
The 4- to 96-h time intervals represent time of nitroglycerin administration after last dose of tadalafil or placebo. Standard deviation for time points ranged
from 10 to 16 beats/min (bpm).
Table 3. Adverse Events
Placebo  Nitrate
(n  161)
Tadalafil  Nitrate
(n  160)
Headache 308 [81] 485 [110]
Myalgia 15 [10] 172 [71]
Back pain 13 [10] 143 [67]
Dizziness 103 [49] 110 [47]
Dyspepsia 3 [3] 74 [41]
Flushing 24 [11] 30 [17]
Postural dizziness 6 [5] 14 [8]
Data are presented as number of adverse events [number of subjects with adverse
event].
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tadalafil. Similar to other PDE5 inhibitors, tadalafil should
not be used in combination with organic nitrates.
Reprint requests and correspondence: Dr. Robert A. Kloner,
Good Samaritan Hospital, Cardiovascular Division, 1225
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